CMND (Clearmind Medicine) Change In Receivables: $-0.09 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMND Clearmind Medicine Inc CMND
22 GF Score
Price $1.81
! 1 Warning Sign
View Full Analysis

What is Clearmind Medicine Change In Receivables?

Clearmind Medicine CMND -5.67% 22 Change In Receivables is $-0.09 Mil as of Apr. 2026. GuruFocus rates CMND with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Clearmind Medicine's change in receivables for the quarter that ended in Apr. 2026 was $-0.02 Mil. It means Clearmind Medicine's Accounts Receivable increased by $0.02 Mil from Jan. 2026 to Apr. 2026 .

Clearmind Medicine's change in receivables for the fiscal year that ended in Oct. 2025 was $0.02 Mil. It means Clearmind Medicine's Accounts Receivable declined by $0.02 Mil from Oct. 2024 to Oct. 2025 .

Clearmind Medicine's Accounts Receivable for the quarter that ended in Apr. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Clearmind Medicine's liquidation value for the three months ended in Apr. 2026 was $10.56 Mil.

Clearmind Medicine  (NAS:CMND) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Clearmind Medicine's Days Sales Outstanding for the quarter that ended in Apr. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Clearmind Medicine's accounts receivable are only considered to be worth 75% of book value:

Clearmind Medicine's liquidation value for the quarter that ended in Apr. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=13.593-3.033+0.75 * 0+0.5 * 0
=10.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearmind Medicine Change In Receivables Related Terms

Clearmind Medicine Change In Receivables Historical Data

* Premium members only.

The historical data trend for Clearmind Medicine's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clearmind Medicine Change In Receivables Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only -0.12 0.02 -0.16 0.07 0.02

Clearmind Medicine Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.01 0.00 -0.08 -0.02
CMND
22GF Score
Clearmind Medicine Inc CMND
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clearmind Medicine Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.09 Mil mean?
Clearmind Medicine (CMND) has a Change In Receivables of $-0.09 Mil as of Apr. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Clearmind Medicine and its competitors.
Is Clearmind Medicine's Change In Receivables too high?
Clearmind Medicine's current Change In Receivables is $-0.09 Mil. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's Change In Receivables compare to CASIF and BIXT?
Clearmind Medicine's Change In Receivables of $-0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Clearmind Medicine and its competitors. Clearmind Medicine's current Change In Receivables is $-0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (CMND) has a current Change In Receivables of $-0.09 Mil. The current Change In Receivables is $-0.09 Mil. Clearmind Medicine's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Clearmind Medicine (CMND), the current Change In Receivables is $-0.09 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clearmind Medicine Business Description

Address 101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H1A5
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score

Get the complete analysis for CMND

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.81
Price